OrthoPediatrics Corp. Reports Third Quarter 2026 Financial Results and Increases 2026 Financial Guidance
OrthoPediatrics reported record Q3 2026 revenue of $72.7 million, up 19% year-over-year, helped nearly 42,000 children, and posted record adjusted EBITDA of $6.9 million. Net loss narrowed to $5.9 million ($0.25 per share) from $11.8 million a year ago, and free cash flow turned positive at $1.6 million, a $5.0 million improvement versus prior-year usage. The company raised full-year 2026 revenue guidance to $270.0-$273.0 million from $265.0-$269.0 million (14-16% growth), reiterated ~$25.0 million adjusted EBITDA expectations, and targeted breakeven annual free cash flow.
Key figures
- Revenue
- 72700000
- Guidance
- FY2026 revenue raised to $270.0M-$273.0M from $265.0M-$269.0M (14-16% growth); adjusted EBITDA ~$25.0M; breakeven free cash flow expected in 2026
- Revenue Yoy
- 19%
- Fcf
- 1600000
- Net loss
- 5900000
- Gross margin
- 74%
- Adjusted ebitda
- 6900000
- Children helped
- nearly 42,000
- Prior year net loss
- 11800000
- Cash and investments
- 44900000
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.